Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients
2018年8月30日 更新者:Jun Zhu、Peking University
Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial
Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial
研究概览
地位
未知
条件
详细说明
Chidamide,a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China.
The aim of this study was to observe the efficacy and safety of Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients.
研究类型
介入性
注册 (预期的)
114
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Jun Zhu, Dr.
- 电话号码:010-88140650
- 邮箱:dreaming2217@hotmai.com
研究联系人备份
- 姓名:Yuqin Song, Dr.
- 电话号码:010-88140650
- 邮箱:songyuqin622@163.com
学习地点
-
-
-
Beijing、中国、100142
- 招聘中
- Beijing Cancer Hospital
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 70年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Histopathology / cytology diagnosed as peripheral T cell lymphoma (PTCL) according to WHO 2016 classification criteria(NK/T cell lymphoma and ALK positive anaplastic large cell lymphoma excluded)including:Peripheral T-cell lymphoma, NOS,Angioimmunoblastic T-cell lymphoma,Anaplastic large-cell lymphoma, ALK negative,Enteropathy-associated T-cell lymphoma,Hepatosplenic T-cell lymphoma,Subcutaneous panniculitis T-cell lymphoma,Mycosis fungoides,Other T-cell lymphoma that investigators consider to be appropriate to be enrolled;
- Patients have received CHOPE regimen for 2 cycles therapy and achieve PR or SD;
- Patients should have at least one evaluable foci ( lymph nodes with diameter≥1.5cm, or evaluable skin foci);
- Age 18-70 years, male or female;
- ECOG performance status 0-2;
- Absolute neutrophil count ≥1.5×109/L, platelet ≥75×109/L, Hb ≥ 90g/L;
- ALT and serum creatinine <1.5 times of normal maximum;
- Life expectancy no less than 3 months;
- Willing to sign the Informed Consent Form.
Exclusion Criteria:
- NK/T cell lymphoma or ALK positive anaplastic large cell lymphoma;
- Female patients in lactation or pregnancy, Childbearing female or male patients unwilling to take contraceptive measures;
- QTc elongation with clinical significance ( male> 450ms, female> 470ms), ventricular tachycardia, atrial fibrillation, cardiac conducting blockage, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease that requires treatment;
- Patients have undergone organ transplantation;
- Patients received symptomatic treatment for bone marrow toxicity within 7 days prior to enrollment;
- Patients with active hemorrhage;
- Patients with or with history of thrombosis, embolism, cerebral hemorrhage, or cerebral infarction;
- Patients with active infection or continuous fever within 14 days prior to enrollment;
- Had major organ surgery within 6 weeks prior to enrollment;
- Impaired liver function ( Total bilirubin > 1.5 times of normal maximum, ALT/AST> 2.5 times of normal maximum, for patients with infiltrative liver disease ALT/AST> 5 times of normal maximum), impaired renal function (serum creatinine> 1.5 times of normal maximum);
- Patients with mental disorders or those do not have the ability to consent;
- Patients with drug abuse, long term alcoholism that may impact the results of the trial;
- Patients with invasion of central nervous system ;
- Non-appropriate patients for the trial according to the judgment of the investigators.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Experimental group
Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
|
Chidamide 15mg orally BIW.
Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
其他名称:
Cyclophosphamide(750mg/m2) was administered intravenously on d1.
Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
|
实验性的:Control group
Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
|
Cyclophosphamide(750mg/m2) was administered intravenously on d1.
Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
complete remission (CR)rate
大体时间:up to 2 years
|
The rate of patients who achieve complete remission after the treatment.
|
up to 2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
objective response rate(ORR)
大体时间:up to 2 years
|
The total proportion of patients with complete response(CR)and partial response(PR).
|
up to 2 years
|
progression-free survival(PFS)
大体时间:2 years
|
Time from treatment until disease progression or death.
|
2 years
|
overall survival(OS)
大体时间:2 years after the last patient's enrollment.
|
From the date of inclusion to date of death, irrespective of any cause.
|
2 years after the last patient's enrollment.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2018年8月28日
初级完成 (预期的)
2020年9月30日
研究完成 (预期的)
2022年9月30日
研究注册日期
首次提交
2018年8月1日
首先提交符合 QC 标准的
2018年8月1日
首次发布 (实际的)
2018年8月6日
研究记录更新
最后更新发布 (实际的)
2018年9月4日
上次提交的符合 QC 标准的更新
2018年8月30日
最后验证
2018年8月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CSIIT-T13
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.